Recombinant Dama dama Ribonuclease pancreatic (RNASE1)

What is Recombinant Dama dama Ribonuclease Pancreatic (RNASE1) and how does it compare to human pancreatic ribonuclease?

Recombinant Dama dama Ribonuclease Pancreatic (RNASE1) is an engineered version of the ribonuclease enzyme derived from fallow deer (Dama dama). Like human pancreatic ribonuclease 1 (hpRNase1), it catalyzes the degradation of RNA by cleaving phosphodiester bonds. Both enzymes belong to the same RNase A superfamily, sharing similar catalytic mechanisms but differing in amino acid sequence, which can affect properties such as thermal stability, catalytic efficiency, and susceptibility to ribonuclease inhibitor (RI) proteins. Research with hpRNase1 has demonstrated its potential anticancer properties when effectively delivered to tumor cells, suggesting similar applications may be possible with the Dama dama variant .

What expression systems are most effective for producing recombinant RNASE1?

Based on research with human pancreatic ribonuclease, Escherichia coli (E. coli) expression systems are commonly used for producing recombinant RNases. Specifically, BL21 and TG1 strains have proven effective. The recombinant protein can be cloned into expression vectors such as pSYN2, tagged with poly-histidine for purification purposes, and expressed following IPTG induction. Purification typically involves immobilized metal affinity chromatography (IMAC) directed against the poly-his tag. Confirmation of protein production can be performed using SDS-PAGE and Western blot analysis with appropriate antibodies . When working with Dama dama RNASE1, researchers should optimize expression conditions including temperature, induction time, and IPTG concentration to maximize yield and proper folding of the active enzyme.

How can I assess the enzymatic activity of recombinant RNASE1?

The ribonucleolytic activity of recombinant RNASE1 can be evaluated using several methodological approaches:

• Gel-based qualitative assays using total RNA as substrate

• Spectrophotometric assays measuring the hydrolysis of RNA or synthetic substrates like cyclic cytidine monophosphate (cCMP)

• Fluorescence-based assays with specially designed fluorogenic substrates

For quantitative assessment, researchers typically measure the enzyme's ability to degrade RNA substrates in the presence of various concentrations of ribonuclease inhibitor (RI) to determine inhibitor evasion capabilities. Comparative analysis with wild-type enzyme provides insights into relative activity. In published studies with hpRNase1, engineered variants have demonstrated up to 2.5-fold greater activity against RNA substrates in the presence of RI compared to wild-type enzymes .

What strategies can be employed to engineer RNASE1 variants that evade ribonuclease inhibitor (RI)?

Engineering RNASE1 variants that evade RI binding is crucial for developing effective therapeutic applications. Several mutation strategies have proven successful:

• Single-point mutations at key interface residues: Targeting amino acids involved in the RI-RNase interaction interface

• Multi-site mutations: Introducing combined mutations (e.g., K8A/N72A/N89A/R92D/E112A in hpRNase1) to disrupt multiple interaction points

• Steric hindrance approaches: Introducing bulky amino acids or modifications that prevent RI binding

• Structure-guided mutations: Using molecular dynamics (MD) simulations to identify optimal mutation sites

For Dama dama RNASE1, researchers should first characterize the RI binding interface through computational modeling and then design mutations based on sequence homology with human variants. In vitro testing should include enzymatic activity assays in the presence of increasing RI concentrations to quantitatively assess inhibitor evasion capacity. Successful engineering has achieved up to 2.5-fold increased activity in the presence of RI compared to wild-type enzymes .

How can recombinant RNASE1 be modified for targeted delivery to specific cell types?

Targeted delivery strategies for recombinant RNASE1 include:

• Fusion with targeting peptides: Attaching cell-specific ligands such as:

  • Gonadotropin-releasing hormone (GnRH) peptide for targeting GnRH receptor-expressing tumor cells

  • Cell-penetrating peptides like HIV-1 TAT protein transduction domain (TAT-PTD) for enhanced cellular uptake

• Antibody-RNASE1 conjugates: Creating immunoRNases by fusing with:

  • Single-chain variable fragments (scFv) against specific tumor markers

  • Full antibodies with tumor-specific targeting capabilities

• Receptor ligand fusion proteins: Incorporating growth factors or cytokines like:

  • Human interleukin-2 (hIL-2) for targeting activated lymphocytes

  • Epidermal growth factor for targeting EGFR-overexpressing cells

The effectiveness of these approaches can be assessed through comparative cytotoxicity studies. For example, research with GnRH-hpRNase1 showed a 26.5-fold decrease in IC50 values compared to non-fused hpRNase1 in GnRH receptor-expressing cancer cells (IC50 of 0.32±0.06 μM for GnRH-hpRNase1 vs 8.49±0.94 μM for hpRNase1) .

What methodologies are most effective for evaluating the cytotoxic effects of engineered RNASE1 variants?

Comprehensive evaluation of cytotoxic effects requires multiple complementary methodologies:

• Cell viability assays:

  • MTT assay for metabolic activity measurement

  • Resazurin-based assays for cell proliferation

  • Colony formation assays for long-term cytotoxic effects

• Cell death mechanism analysis:

  • Flow cytometry with Annexin V/PI staining for apoptosis detection

  • Caspase activation assays

  • TUNEL assay for DNA fragmentation

• Target specificity assessment:

  • Comparative cytotoxicity in receptor-positive vs. receptor-negative cell lines

  • Competitive binding assays with unlabeled ligand

  • Fluorescently labeled protein uptake studies

Table 1: Comparative cytotoxic effects of hpRNase1 and GnRH-hpRNase1 on different cell lines (adapted from published data on human pancreatic RNase1)

What are the critical factors to consider when designing experiments to compare wild-type and engineered RNASE1 variants?

When designing comparative experiments between wild-type and engineered Dama dama RNASE1 variants, researchers should consider:

• Protein purity and concentration standardization:

  • Ensure comparable purity levels (>95%) using standardized purification protocols

  • Normalize protein concentrations precisely using BCA or Bradford assays

  • Verify enzyme integrity through circular dichroism spectroscopy

• Activity normalization:

  • Determine specific activity against standard substrates

  • Normalize doses based on activity rather than protein concentration when comparing variants

• Appropriate controls:

  • Include catalytically inactive mutants to distinguish between ribonucleolytic and non-specific effects

  • Use unrelated proteins of similar size (e.g., GFP) as negative controls

  • Include commercially available RNases as reference standards

• Dose-response relationships:

  • Establish complete dose-response curves (at least 6-8 concentrations)

  • Calculate and compare IC50 values using appropriate statistical models

  • Assess time-dependent effects at multiple timepoints (24h, 48h, 72h)

How can researchers effectively analyze the structure-function relationship of RNASE1 variants?

A comprehensive approach to structure-function analysis includes:

• Computational methods:

  • Molecular dynamics (MD) simulations of native and mutant RNASE1 in free and RI-bound forms

  • Protein-protein interaction modeling

  • Electronic structure calculations to analyze catalytic mechanisms

• Biophysical characterization:

  • Circular dichroism spectroscopy for secondary structure analysis

  • Differential scanning calorimetry for thermal stability assessment

  • Surface plasmon resonance for binding kinetics with RI and target receptors

• Structure determination:

  • X-ray crystallography of enzyme-substrate complexes

  • NMR spectroscopy for solution structure and dynamics

  • Cryo-EM for larger complexes with targeting moieties

• Mutational analysis:

  • Alanine scanning of key residues

  • Charge reversal mutations at electrostatic interaction sites

  • Conservative vs. non-conservative substitutions

Correlating structural changes with functional outcomes through systematic mutation studies can identify key determinants of activity, stability, and target specificity. For example, published research has demonstrated that specific mutations (K8A/N72A/N89A/R92D/E112A) in human pancreatic RNase1 led to 2.5-fold increased activity against RNA substrates in the presence of RI .

What tumor types are most suitable for targeting with engineered RNASE1?

Based on research with human pancreatic ribonuclease, the most promising tumor types for RNASE1-based therapeutics include:

• Hormone-responsive tumors:

  • Prostate cancer cells (e.g., PC-3, LNCaP) expressing GnRH receptors

  • Breast cancer cells expressing specific hormone receptors

  • Ovarian cancer with hormone receptor overexpression

• Tumors with receptor overexpression:

  • ErbB2/HER2-positive tumors (e.g., SK-BR-3, MDA-MB453 cell lines)

  • EGFR-overexpressing tumors

  • Transferrin receptor-positive malignancies

  • CD30+ lymphomas

  • Triple-negative breast cancers with nucleolin (NCL) overexpression

Selection criteria should include receptor expression profiling and sensitivity to RNA degradation. The cytotoxic effect of targeted RNASE1 appears to be most profound in rapidly proliferating cells with high RNA synthesis rates and metabolic activity.

How does the mechanism of action of RNASE1 compare with other nucleases used in cancer research?

The mechanism of action of RNASE1 differs from other nucleases in several key aspects:

• Target specificity:

  • RNASE1 specifically degrades RNA (not DNA)

  • DNases target DNA structures

  • Dual nucleases can affect both RNA and DNA

• Cellular effects:

  • RNASE1 primarily disrupts protein synthesis by degrading mRNA and other RNAs

  • Induces apoptosis through RNA degradation and subsequent cell cycle arrest

  • Abrogates protein biosynthesis without direct DNA damage

• Delivery requirements:

  • Must reach cytoplasm to exert cytotoxicity

  • Requires strategies to overcome cellular uptake limitations

  • Needs to evade ribonuclease inhibitor proteins

• Resistance mechanisms:

  • Primary resistance through ribonuclease inhibitor binding

  • Secondary resistance through altered endocytic pathways

  • Reduced expression of target receptors

When engineered with targeting moieties, RNASE1 represents a potentially less immunogenic alternative to plant and bacterial toxins, which often exhibit non-specific toxic effects and high immunogenicity .

What strategies can overcome limitations in recombinant RNASE1 expression and purification?

Common challenges and their solutions include:

• Inclusion body formation:

  • Lower induction temperature (16-20°C)

  • Reduce IPTG concentration (0.1-0.5 mM)

  • Co-express with chaperone proteins

  • Use specialized E. coli strains like Origami™ or SHuffle®

• Ribonuclease contamination concerns:

  • Implement strict RNase-free laboratory practices

  • Use DEPC-treated water and reagents

  • Include RNase inhibitors during non-functional characterization steps

  • Employ specialized purification protocols with RNase monitoring

• Purification challenges:

  • Optimize IMAC conditions (pH, imidazole gradient)

  • Consider alternative tags (Strep-tag II, FLAG tag)

  • Implement multi-step purification strategies

  • Use size exclusion chromatography as a final polishing step

• Activity preservation:

  • Include reducing agents during purification

  • Optimize buffer composition and pH

  • Add stabilizers like glycerol or sucrose

  • Implement gentle elution conditions

Researchers have successfully expressed and purified active hpRNase1 variants in E. coli using IMAC directed against poly-his tags, with protein products verified by SDS-PAGE and Western blot analysis .

How can researchers accurately assess the in vivo efficacy of engineered RNASE1 variants?

A comprehensive in vivo assessment framework includes:

• Appropriate tumor models:

  • Xenograft models with receptor-positive and receptor-negative tumors

  • Patient-derived xenografts for clinical relevance

  • Orthotopic models to recapitulate tumor microenvironment

  • Genetically engineered mouse models for spontaneous tumors

• Pharmacokinetic/pharmacodynamic studies:

  • Radiolabeling or fluorescent labeling for distribution studies

  • Serial blood sampling for half-life determination

  • Tumor and tissue accumulation assessment

  • Dose-finding studies with multiple endpoints

• Efficacy parameters:

  • Tumor growth inhibition measurements

  • Survival analysis

  • Molecular response markers (RNA integrity in tumors)

  • Immunohistochemical evaluation of target engagement

• Toxicity assessment:

  • Complete blood counts for hematological toxicity

  • Serum chemistry for organ function

  • Histopathological examination of major organs

  • Immunogenicity evaluation

Considering the promising in vitro results with targeted hpRNase1 variants, researchers working with Dama dama RNASE1 should evaluate their constructs in GnRH-R-expressing tumor xenografts to validate anti-tumor effects in vivo .

What are promising combination strategies for enhancing the therapeutic efficacy of engineered RNASE1?

Several combination approaches warrant investigation:

• Combination with conventional chemotherapeutics:

  • RNase treatment followed by DNA-damaging agents

  • Simultaneous administration with microtubule inhibitors

  • Sequential therapy with antimetabolites

• Immunomodulatory combinations:

  • Co-administration with immune checkpoint inhibitors

  • Combination with CAR-T cell therapy

  • Use with cancer vaccines to enhance immune recognition

• Targeted therapy combinations:

  • Synergy with kinase inhibitors targeting complementary pathways

  • Co-delivery with siRNA targeting resistance mechanisms

  • Combination with antibody-drug conjugates

• Delivery system enhancements:

  • Co-encapsulation in nanoparticles with membrane-disrupting agents

  • Use of endosome-disrupting peptides

  • Extracellular vesicle-mediated delivery

Mechanistic studies suggest that RNASE1-based therapeutics could sensitize cancer cells to conventional treatments by disrupting protective RNA networks and protein synthesis, potentially overcoming resistance mechanisms .

How can advanced computational approaches advance RNASE1 engineering?

Modern computational approaches offer powerful tools for RNASE1 engineering:

• AI-driven protein design:

  • Machine learning algorithms to predict optimal mutation combinations

  • Deep learning models for stability and activity prediction

  • Generative models for novel sequence design

• Advanced molecular dynamics:

  • Enhanced sampling techniques for conformational exploration

  • Free energy calculations for binding affinity prediction

  • Coarse-grained simulations for large-scale dynamics

• Systems biology integration:

  • Network analysis to identify optimal RNA targets

  • Pathway modeling to predict cellular responses

  • Multi-scale modeling linking molecular mechanisms to cellular effects

• Quantum mechanical approaches:

  • QM/MM methods for detailed catalytic mechanism study

  • Electronic structure calculations for transition state analysis

  • Reaction coordinate mapping for improved catalytic efficiency

Published research has already demonstrated the value of molecular dynamics simulations in engineering human pancreatic RNase1 variants, suggesting similar approaches would benefit Dama dama RNASE1 development .